The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib
British journal of haematology (2013) - Comments
pubmed: 23360303  doi: 10.1111/bjh.12206  issn: 1365-2141  issn: 0007-1048 

Girija Dasmahapatra, Hiral Patel, Paul Dent, Richard I. Fisher, Jonathan Friedberg, Steven Grant